Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of “Moderate Buy” by Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $19.1111.

FULC has been the subject of a number of research reports. Leerink Partners set a $20.00 price target on shares of Fulcrum Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. The Goldman Sachs Group reiterated a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Piper Sandler reissued an “overweight” rating and issued a $23.00 target price (up previously from $16.00) on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Royal Bank Of Canada lifted their price target on Fulcrum Therapeutics from $7.00 to $10.00 and gave the stock a “sector perform” rating in a research note on Monday, December 8th. Finally, Wall Street Zen cut Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th.

Fulcrum Therapeutics Trading Up 0.3%

Shares of FULC opened at $10.66 on Friday. Fulcrum Therapeutics has a 12-month low of $2.32 and a 12-month high of $15.74. The company has a market cap of $576.92 million, a PE ratio of -9.03 and a beta of 3.19. The stock has a 50-day moving average price of $11.03 and a 200-day moving average price of $9.35.

Insider Activity at Fulcrum Therapeutics

In other news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the sale, the insider directly owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. The trade was a 40.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the sale, the director directly owned 469,864 shares of the company’s stock, valued at $5,577,285.68. This trade represents a 3.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Fulcrum Therapeutics during the 4th quarter valued at about $30,000. Meeder Asset Management Inc. bought a new stake in Fulcrum Therapeutics in the fourth quarter valued at approximately $39,000. Quarry LP purchased a new stake in shares of Fulcrum Therapeutics during the third quarter valued at approximately $35,000. Persistent Asset Partners Ltd purchased a new stake in shares of Fulcrum Therapeutics during the fourth quarter valued at approximately $75,000. Finally, Farther Finance Advisors LLC grew its holdings in shares of Fulcrum Therapeutics by 108.3% in the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after purchasing an additional 3,697 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.